Literature DB >> 25680699

Molecular and immunological biomarkers to predict IVIg response.

Caroline Galeotti1, Srini V Kaveri2, Jagadeesh Bayry3.   

Abstract

Some patients with autoimmune and inflammatory diseases treated with intravenous immunoglobulin G (IVIg) as a first line therapy are refractory. Identification of predictive biomarker(s) to segregate responders and non-responders to IVIg therapy remains critical. A number of biomarkers, particularly in Kawasaki disease, have shown potential for predicting response to IVIg.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fcγ receptor; Guillain-Barré syndrome; Kawasaki disease; cytokines; immune thrombocytopenia; intravenous immunoglobulin

Mesh：

Substances：

Year:  2015        PMID： 25680699     DOI： 10.1016/j.molmed.2015.01.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  20 in total

1.  Identification of Differentially Expressed Genes in Kawasaki Disease Patients as Potential Biomarkers for IVIG Sensitivity by Bioinformatics Analysis.

Authors:  Lan He; Youyu Sheng; Chunyun Huang; Guoying Huang
Journal:  Pediatr Cardiol       Date:  2016-05-09       Impact factor: 1.655

2.  Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages.

Authors:  Chaitrali Saha; Prathap Kothapalli; Veerupaxagouda Patil; Gundallahalli Bayyappa ManjunathaReddy; Srini V Kaveri; Jagadeesh Bayry
Journal:  Hum Vaccin Immunother       Date:  2019-05-07       Impact factor: 3.452

3.  Relationship between IL-27 and coronary arterial lesions in children with Kawasaki disease.

Authors:  Feifei Si; Yao Wu; Fang Gao; Siqi Feng; Ruixi Liu; Qijian Yi
Journal:  Clin Exp Med       Date:  2017-01-20       Impact factor: 3.984

Review 4.  Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.

Authors:  Arno Kornberg
Journal:  World J Hepatol       Date:  2015-06-18

5.  Unique Molecular Patterns Uncovered in Kawasaki Disease Patients with Elevated Serum Gamma Glutamyl Transferase Levels: Implications for Intravenous Immunoglobulin Responsiveness.

Authors:  Yue Wang; Zhen Li; Guang Hu; Shiying Hao; Xiaohong Deng; Min Huang; Miao Ren; Xiyuan Jiang; John T Kanegaye; Kee-Soo Ha; JungHwa Lee; Xiaofeng Li; Xuejun Jiang; Yunxian Yu; Adriana H Tremoulet; Jane C Burns; John C Whitin; Andrew Y Shin; Karl G Sylvester; Doff B McElhinney; Harvey J Cohen; Xuefeng B Ling
Journal:  PLoS One       Date:  2016-12-21       Impact factor: 3.240

6.  A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease.

Authors:  Seiichiro Takeshita; Takashi Kanai; Yoichi Kawamura; Yusuke Yoshida; Shigeaki Nonoyama
Journal:  PLoS One       Date:  2017-05-23       Impact factor: 3.240

7.  Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.

Authors:  Marie Matignon; Caroline Pilon; Morgane Commereuc; Cynthia Grondin; Claire Leibler; Tomek Kofman; Vincent Audard; José Cohen; Florence Canoui-Poitrine; Philippe Grimbert
Journal:  PLoS One       Date:  2017-06-27       Impact factor: 3.240

Review 8.  Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored.

Authors:  Ying Wang; Shuang Sun; Jie Zhu; Li Cui; Hong-Liang Zhang
Journal:  Mediators Inflamm       Date:  2015-09-16       Impact factor: 4.711

9.  Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin.

Authors:  Caroline Galeotti; Pushpa Hegde; Mrinmoy Das; Emmanuel Stephen-Victor; Fernando Canale; Marcos Muñoz; Varun K Sharma; Jordan D Dimitrov; Srini V Kaveri; Jagadeesh Bayry
Journal:  Sci Rep       Date:  2016-01-22       Impact factor: 4.379

10.  FCN1 (M-ficolin), which directly associates with immunoglobulin G1, is a molecular target of intravenous immunoglobulin therapy for Kawasaki disease.

Authors:  Daisuke Okuzaki; Kaori Ota; Shin-Ichi Takatsuki; Yukari Akiyoshi; Kazuyuki Naoi; Norikazu Yabuta; Tsutomu Saji; Hiroshi Nojima
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.